Table 4. Overall survival: Explanatory prognostic factors in a Cox proportional Hazards model for the full study collective and for subgroups depending on adjuvant therapy, tumor histology, tumor size and lymph node status.
Prognostic groups | Prognostic factor | p-value | HR1(95% CI)2 | |
---|---|---|---|---|
All NSCLC patients (n = 301) | Age | 0.005 | 1.545 (1.147–2.080) | |
Tumor stage | <0.001 | 1.986 (1.492–2.645) | ||
Sex | 0.006 | 1.658 (1.132–2.429) | ||
Adjuvant therapy | No adjuvant therapy (n = 255) | PD-1 | 0.035 | 0.659 (0.440–0.987) |
Age | 0.019 | 1.471 (1.070–2.021) | ||
Tumor size | 0.016 | 1.563 (1.074–2.275) | ||
Tumor stage | <0.001 | 1.928 (1.382–2.690) | ||
Adjuvant therapy (n = 46) | PD-L1 | 0.012 | 0.353 (0.145–0.861) | |
Tumor histology | Non squamous cell carcinoma (n = 163) | PD-1 | 0.030 | 0.561 (0.322–0.977) |
Age | 0.016 | 1.704 (1.118–2.598) | ||
Sex | 0.032 | 1.663 (1.028–2.688) | ||
Tumor size | 0.043 | 1.627 (1.001–2.646) | ||
Lymph node status | 0.001 | 2.049 (1.351–3.107) | ||
Squamous cell carcinoma (n = 138) | PD-L1 | 0.005 | 0.459 (0.252–0.833) | |
Tumor stage | 0.002 | 1.929 (1.277–2.913) | ||
Tumor size | pT1 (n = 93) | Sex | 0.002 | 2.860 (1.361–6.010) |
Tumor stage | 0.005 | 2.615 (1.389–4.922) | ||
pT2-4 (n = 208) | PD-L1 | 0.004 | 0.556 (0.366–0.844) | |
PD-1 | 0.023 | 0.626 (0.410–0.954) | ||
Age | 0.041 | 1.429 (1.020–2.001) | ||
Lymph node status | 0.001 | 1.783 (1.279–2.486) | ||
Lymph node status | pN0 (n = 192) | Age | 0.009 | 1.671 (1.140–2.449) |
Tumor size | 0.004 | 1.809 (1.191–2.747) | ||
pN1-3 (n = 109) | PD-L1 | 0.005 | 0.470 (0.268–0.825) |